To report a case of gelatinous drop-like corneal dystrophy (GDLD) caused by a novel homozygous tumor-associated calcium signal transducer 2 ( TACSTD2 ) gene mutation and summarize the correlations of clinical phenotypes and genotypes in patients with GDLD. We analyzed the clinical characteristics and treatment outcomes of a 42-year-old man with GDLD. The patient with GDLD received multiple keratoplasties, and histopathological staining of the corneal sections was performed. We performed genetic testing and clinical evaluations on all family members. In addition, we conducted a literature review of previously reported patients with GDLD with pathogenic TACSTD2 gene mutations. Genetic sequencing of the proband identified a novel nonsense homozygous mutation c.588C > A in the TACSTD2 gene. The histopathological analysis revealed intense amyloid deposition in the subepithelial region of the cornea. We summarized the clinical features of patients with GDLD with 33 previously reported TACSTD2 gene mutations. This study reported a novel homozygous nonsense mutation in a Chinese patient with GDLD, thereby expanding the mutation spectrum of the TACSTD2 gene.

Gelatinous drop-like corneal dystrophy (GDLD) is a rare autosomal recessive eye disease. GDLD is characterized by the loss of barrier function in corneal epithelial cells (CECs) and amyloid deposition due to pathogenic variants in the TACSTD2 gene. Limbal stem cell transplantation (LSCT) has been suggested as an effective therapeutic alternative for patients with GDLD. However, despite LSCT, amyloid deposition recurs in some patients. The pathogenesis of recurrence is poorly studied. We present the case of a patient with GDLD. Genetic analysis revealed a homozygous deletion, NM_002353.3:c.653del, in the TACSTD2 gene. Functional analysis in a cell model system revealed the loss of the transmembrane domain and subcellular protein mislocalization. The patient with GDLD underwent direct allogeneic LSCT with epithelial debridement followed by deep anterior lamellar keratoplasty 10 months later due to amyloid deposition and deterioration of vision. Taken together, the results of transcriptome analysis and immunofluorescence staining of post-LSCT corneal sample with amyloid deposits obtained during keratoplasty demonstrated complete restoration of wild-type TACSTD2 expression, indicating that donor CECs replaced host CECs. Our study provides experimental evidence that amyloid deposition can recur after LSCT despite complete restoration of wild-type TACSTD2 expression.

Endoplasmic reticulum (ER) retention of misfolded glycoproteins is mediated by the ER-localized eukaryotic glycoprotein secretion checkpoint, UDP-glucose glycoprotein glucosyl-transferase (UGGT). The enzyme recognizes a misfolded glycoprotein and flags it for ER retention by re-glucosylating one of its N-linked glycans. In the background of a congenital mutation in a secreted glycoprotein gene, UGGT-mediated ER retention can cause rare disease, even if the mutant glycoprotein retains activity ("responsive mutant"). Using confocal laser scanning microscopy, we investigated here the subcellular localization of the human Trop-2-Q118E, E227K and L186P mutants, which cause gelatinous drop-like corneal dystrophy (GDLD). Compared with the wild-type Trop-2, which is correctly localized at the plasma membrane, these Trop-2 mutants are retained in the ER. We studied fluorescent chimeras of the Trop-2 Q118E, E227K and L186P mutants in mammalian cells harboring CRISPR/Cas9-mediated inhibition of the UGGT1 and/or UGGT2 genes. The membrane localization of the Trop-2 Q118E, E227K and L186P mutants was successfully rescued in UGGT1-/- cells. UGGT1 also efficiently reglucosylated Trop-2-Q118E-EYFP in cellula. The study supports the hypothesis that UGGT1 modulation would constitute a novel therapeutic strategy for the treatment of pathological conditions associated to misfolded membrane glycoproteins (whenever the mutation impairs but does not abrogate function), and it encourages the testing of modulators of ER glycoprotein folding quality control as broad-spectrum rescue-of-secretion drugs in rare diseases caused by responsive secreted glycoprotein mutants. Corneal dystrophy (CD) is most recently defined as a collection of rare hereditary non-inflammatory disorders of abnormal deposition of substances in the cornea. CD was coined in 1890 by Arthur Groenouw and Hugo Biber, and the efforts of Ernst Fuchs, Wilhelm Uhthoff, and Yoshiharu Yoshida solidified the foundation of the understanding of these diseases. As proposed in 2015 by the International Classification of Corneal Dystrophies (IC3D), CD is sub-classified by the anatomic location affected: epithelial/subepithelial, epithelial-stromal, stromal, and endothelial dystrophies. Discoveries and unique case studies continue to broaden our understanding and classification of these diseases; therefore, it is difficult to categorize every single dystrophy solely into these four major labels.   The objective of this article is to present an overview of the evaluation and management for the most prominent and understood variants of CD. Highlights of these dystrophies will be discussed. However, further in-depth discussion on these dystrophies will be in separate StatPearls articles.  Patients with CD can be asymptomatic, but if symptoms occur, they typically experience bilateral visual acuity loss, typically in the form of irregular astigmatism. Depending on the corneal layer affected, patients may also manifest with photophobia, dry eyes, corneal edema, and recurrent corneal erosions, especially with epithelial-based CD, which causes considerable pain. Symptoms can begin at any age, depending on the diagnosis. Treatment can range from conservative measures to corneal transplantation.   CD is a significant but rare ocular disease. The genetic component of this disease is important for patients to understand, especially for affected patients involved with family planning. As we begin to understand genetics in greater detail, better evaluation and treatments for CD will come to fruition.  The objective of this article is to present an overview of the general evaluation and management for the most prominent and understood variants of CD. Highlights of these dystrophies will be covered, but the author intends to elaborate on these dystrophies separately in other StatPearls articles. The variants of CD based on their new anatomic classifications in IC3D are:  Epithelial and subepithelial dystrophies  : Epithelial basement membrane corneal dystrophy (EBMCD), also previously known as map-finger-dot dystrophy, Cogan microcystic dystrophy, and anterior basement membrane dystrophy. . Epithelial recurrent erosion dystrophies (EREDs) which includes Franceschetti corneal dystrophy, dystrophia smolandiensis, and dystrophia helsinglandica . Subepithelial mucinous corneal dystrophy (SMCD) . Meesmann corneal dystrophy (MECD) also known as juvenile epithelial corneal dystrophy . Lisch epithelial corneal dystrophy (LECD) . Gelatinous drop-like corneal dystrophy (GDLD) . Epithelial-Stromal Dystrophies (still included under epithelial and subepithelial dystrophies) : Lattice corneal dystrophy (LCD), with its subtypes: type I (TGFBI mutation) and type II (familial amyloidosis Finnish type), including LCD variants . Granular corneal dystrophy (GCD), types I and II (Avellino-type)  . Reis-Bückler’s corneal dystrophy (RBCD) . Thiel-Behnke corneal dystrophy (honeycomb dystrophy) (TBCD) . Stromal dystrophies: Macular corneal dystrophy (MCD)  . Schnyder corneal dystrophy (SCD)  . Congenital stromal corneal dystrophy (CSCD)  . Fleck corneal dystrophy (FCD)  . Posterior amorphous corneal dystrophy (PACD)  . Pre-Descemet corneal dystrophy (PDCD)  . Central cloudy dystrophy of francois (CCDF) . Endothelial Corneal Dystrophies: Fuchs endothelial corneal dystrophy (FECD)  . Posterior polymorphous corneal dystrophy (PPCD)  . Congenital hereditary endothelial dystrophy (CHED)  . X-linked endothelial corneal dystrophy (XECD) .

The advent of high throughput DNA sequencing is providing massive amounts of tumor-associated mutation data. Implicit in these analyses is the assumption that, by acquiring a series of hallmark changes, normal cells evolve along a neoplastic path. However, the lack of correlation between cancer risk and global exposure to mutagenic factors provides arguments against this model. This suggested that additional, non-mutagenic factors are at work in cancer development. A candidate determinant is TROP2, that stands out for its expression in the majority of solid tumors in human, for its impact on the prognosis of most solid cancers and for its role as driver of cancer growth and metastatic diffusion, through overexpression as a wild-type form. The Trop-2 signaling network encompasses CREB1, Jun, NF-κB, Rb, STAT1 and STAT3, through induction of cyclin D1 and MAPK/ERK. Notably, Trop-2-driven pathways vastly overlap with those activated by most functionally relevant/most frequently mutated RAS and TP53, and are co-expressed in a large fraction of individual tumor cases, suggesting functional overlap. Mutated Ras was shown to synergize with the TROP2-CYCLIND1 mRNA chimera in transforming primary cells into tumorigenic ones. Genomic loss of TROP2 was found to promote carcinogenesis in squamous cell carcinomas through modulation of Src and mutated Ras pathways. DNA methylation and TP53 status were shown to cause genome instability and TROP gene amplification, together with Trop-2 protein overexpression. These findings suggest that mutagenic and the TROP2 non-mutagenic pathways deeply intertwine in driving transformed cell growth and malignant progression of solid cancers.

BACKGROUND: This report presents a unique case that illustrates the importance of ocular history and photo documentation of ophthalmologic pathology when waivers are granted.CASE REPORT: A United States Navy pilot applicant was granted a waiver for a corneal scar of unknown etiology. He chose not to pursue Navy pilot training and reenrolled as a United States Marine Corps pilot applicant. He did not mention the previous waiver or subsequent civilian surgical corneal treatment for Salzmann's nodular degeneration and was diagnosed with gelatinous drop-like corneal dystrophy. Eventually all information was disclosed, and the diagnosis was changed to postoperative changes from previous Salzmann's nodule removal, which is disqualifying for Marine Corps pilot applicants.DISCUSSION: Corneal dystrophy and degeneration are disqualifying conditions for military pilot applicants. A detailed history, to include surgical history, must be disclosed by the applicant. Photo documentation and appropriate topographic studies should also be completed and reviewed when waivers for corneal pathology are considered.Thorgrimson JL, Hessert DD. Salzmann's nodular degeneration in a pilot applicant. Aerosp Med Hum Perform. 2023; 94(5):400-403.